Ginkgo Bioworks Holdings Inc vs Diamondback Energy Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.25 (market cap $505.73M), while Diamondback Energy Inc trades at $199.23 (market cap $56.48B). The key difference: Diamondback Energy Inc is far larger — about 111.7× Ginkgo Bioworks Holdings Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | FANG | |
|---|---|---|
Market Cap | $505.73M | $56.48B |
Sector | Health | Energy |
52-Week High | $16.14 | $213.69 |
52-Week Low | $5.48 | $134.53 |
Enterprise Value | $607.68M | $68.63B |
Dividend Yield | — | 2.18% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Diamondback Energy (FANG) trades at $200.97, up 1.01% today, with bullish technical signals and strong earnings beats in Q1 and Q2 2026. The stock benefits from high oil prices, production growth, and a 90% analyst buy rating. Recent news highlights Q2 earnings surpassing estimates, driven by operational efficiency and raised 2026 output guidance. Cash flow from operations improved to $8.76 billion in 2025, though net income margin declined to 8.64%.
The outlook is positive, with a consensus price target of $236.63 offering ~18% upside, supported by debt reduction and Permian Basin strength. Risks include oil price volatility, margin pressure from rising costs, and geopolitical supply disruptions affecting global markets. Institutional inflows, like Balefire LLC's recent purchase, reinforce confidence in growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →